Company Overview - Crinetics Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing oral therapies for rare endocrine disorders and endocrine-related tumors [6] - The company has a market capitalization of $3.97 billion and reported a revenue of $7.7 million for the trailing twelve months (TTM) [4] - Crinetics has a net income of -$465.32 million for the TTM, indicating ongoing investment in research and development [4] Recent Developments - Rogerio Vivaldi Coelho, a director at Crinetics, sold 5,000 shares of common stock on March 12, 2026, for approximately $181,000, which represents 23.47% of his direct common stock holdings [1][2][7] - The sale was executed under a Rule 10b5-1 trading plan, indicating it was a pre-scheduled liquidity move rather than a signal of lack of confidence in the company [7][9] - The shares were sold at a weighted average price of $36.15, closely aligned with the market close price of $36.51 on the same day [7] Product Pipeline and Market Position - Crinetics is advancing a pipeline of novel small-molecule therapeutics, with key clinical-stage candidates including Paltusotine, CRN04777, and CRN04894 [8] - The company is transitioning from development to early commercialization, having generated $7.7 million in revenue for 2025, largely from its lead drug, Palsonify, which earned $5.4 million in its first quarter [10] - Crinetics is expanding its pipeline internationally, recently submitting a marketing application for Palsonify in Brazil, supported by data from 18 clinical trials [11] Financial Position - The company has over $1.4 billion in cash post-offering, positioning it well for future growth despite high annual R&D spending exceeding $330 million [10][11]